Eli Lilly and Company (LLY)
Automate Your Wheel Strategy on LLY
With Tiblio's Option Bot, you can configure your own wheel strategy including LLY - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol LLY
- Rev/Share 66.2502
- Book/Share 26.5925
- PB 41.7334
- Debt/Equity 1.7865
- CurrentRatio 1.5463
- ROIC 0.286
- MktCap 992485244666.0
- FreeCF/Share 10.0576
- PFCF 110.0231
- PE 53.9306
- Debt/Assets 0.3698
- DivYield 0.0054
- ROE 1.0226
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 4
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Resumed | LLY | UBS | -- | Buy | -- | $1250 | Jan. 7, 2026 |
| Upgrade | LLY | Daiwa Securities | Neutral | Buy | -- | $1230 | Dec. 16, 2025 |
| Reiterated | LLY | BofA Securities | -- | Buy | $1286 | $1268 | Dec. 15, 2025 |
| Reiterated | LLY | Goldman | -- | Buy | $951 | $1145 | Dec. 15, 2025 |
| Initiation | LLY | Scotiabank | -- | Sector Outperform | -- | $1165 | Nov. 13, 2025 |
| Upgrade | LLY | Leerink Partners | Market Perform | Outperform | -- | $1104 | Nov. 10, 2025 |
| Reiterated | LLY | BMO Capital Markets | -- | Outperform | $840 | $930 | Oct. 20, 2025 |
| Upgrade | LLY | Erste Group | Hold | Buy | -- | -- | Oct. 14, 2025 |
| Downgrade | LLY | Berenberg | Buy | Hold | -- | $830 | Sept. 17, 2025 |
| Upgrade | LLY | HSBC Securities | Reduce | Hold | -- | $700 | Aug. 27, 2025 |
News
Lilly declares fourth-quarter 2025 dividend
Published: October 27, 2025 by: PRNewsWire
Sentiment: Neutral
INDIANAPOLIS , Oct. 27, 2025 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the fourth quarter of 2025 of $1.50 per share on outstanding common stock. The dividend is payable on December 10, 2025, to shareholders of record at the close of business on November 14, 2025.
Read More
Baron Health Care Fund Q3 2025 Top Contributors And Detractors
Published: October 27, 2025 by: Seeking Alpha
Sentiment: Neutral
Argenx SE is a biotechnology company best known for developing Vyvgart, the leading FcRn inhibitor for the treatment of autoimmune conditions. RadNet, Inc. is the largest operator of outpatient diagnostic imaging services and related solutions in the U.S. Intuitive Surgical, Inc. manufactures the da Vinci Surgical System, a robotic surgical system used for minimally invasive surgical procedures.
Read More
What's in Store for These 5 Pharma Bigwigs This Earnings Season?
Published: October 27, 2025 by: Zacks Investment Research
Sentiment: Neutral
As earnings season accelerates, pharma heavyweights LLY, MRK, ABBV, BMY and GILD prepare to reveal their Q3 results amid a strong sector start.
Read More
Buy, Sell or Hold Lilly Stock? Key Tips Ahead of Q3 Earnings
Published: October 27, 2025 by: Zacks Investment Research
Sentiment: Neutral
Eli Lilly's Q3 results hinge on strong demand for Mounjaro and Zepbound as investors weigh growth drivers against the pressure of pricing and competition.
Read More
Seeking Clues to Lilly (LLY) Q3 Earnings? A Peek Into Wall Street Projections for Key Metrics
Published: October 27, 2025 by: Zacks Investment Research
Sentiment: Positive
Besides Wall Street's top-and-bottom-line estimates for Lilly (LLY), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2025.
Read More
Here's How Eli Lilly's Oncology Drugs Are Poised Ahead of Q3 Earnings
Published: October 24, 2025 by: Zacks Investment Research
Sentiment: Positive
LLY's oncology portfolio, led by Verzenio, is set for double-digit growth as investors eye Q3 results beyond its obesity drugs.
Read More
Eli Lilly: Time To Buy LLY Stock?
Published: October 24, 2025 by: Forbes
Sentiment: Positive
Eli Lilly stock (NYSE: LLY) is up 10% this month, a rise driven by strong clinical trial progress. This includes the announcement of positive Phase 3 results in October 2025 for its oral GLP-1 drug, orforglipron, specifically for diabetes management and weight loss.
Read More
Lilly Up 10% in a Month: Should You Buy, Sell or Hold the Stock?
Published: October 23, 2025 by: Zacks Investment Research
Sentiment: Positive
Lilly stock climbs nearly 10% in a month amid a broader recovery in the drug and biotech sector.
Read More
Eli Lilly (LLY) Earnings Expected to Grow: Should You Buy?
Published: October 23, 2025 by: Zacks Investment Research
Sentiment: Neutral
Lilly (LLY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
Eli Lilly Q3 earnings eyed for insights into drug pricing policies, obesity and diabetes drug performance
Published: October 20, 2025 by: Proactive Investors
Sentiment: Neutral
Eli Lilly and Co (NYSE:LLY) will report its third quarter 2025 earnings next Thursday, with Bank of America analysts closely watching how the company's obesity and diabetes treatments are performing amid ongoing policy debates over US drug pricing. The firm believes the drugmaker's upcoming report could offer insight into the company's key brands while highlighting broader industry trends affecting margins and growth.
Read More
My Top 3 Pharma Stocks
Published: October 20, 2025 by: Seeking Alpha
Sentiment: Positive
Obesity, type 2 diabetes, and cancer continue to grow across the globe, but pharma stocks remain off the radars of many investors. Many of them consistently beat the Street's consensus estimates and offer dividend yields even higher than IT, as well as oil and gas stocks. In this article, I reveal my top 3 Big Pharma players.
Read More
Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It
Published: October 20, 2025 by: Zacks Investment Research
Sentiment: Positive
Zacks.com users have recently been watching Lilly (LLY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Read More
NVO and LLY Stocks Slide as Trump Signals Price Cuts for GLP-1 Drugs
Published: October 17, 2025 by: Zacks Investment Research
Sentiment: Negative
Trump's pledge to slash GLP-1 drug prices sends Novo Nordisk and Eli Lilly shares tumbling, raising questions about the feasibility of such a development.
Read More
Here's What Trump Said That's Pressuring Novo Nordisk and Eli Lilly Stocks
Published: October 17, 2025 by: Investopedia
Sentiment: Negative
Novo Nordisk (NVO) and Eli Lilly (LLY) shares slumped in early trading Friday after President Trump promised to lower the prices of popular weight-loss drugs, such as Novo Nordisk's Ozempic and Eli Lilly's Zepbound.
Read More
Is Trump Going to Kill the GLP-1 Cash Cow?
Published: October 17, 2025 by: 24/7 Wall Street
Sentiment: Negative
GLP-1 drugs propelled Novo Nordisk (NVO) and Eli Lilly (LLY) to record profits, with sales exceeding $20 billion amid skyrocketing demand. Both companies cut prices recently to expand access, but President Trump's vow threatens deeper reductions.
Read More
Novo Vs. Lilly Vs. Pfizer: Who Wins If Trump Slashes The Price Of Weight Loss Drugs?
Published: October 17, 2025 by: Benzinga
Sentiment: Negative
President Donald Trump just dropped a political bomb into one of Wall Street's hottest trades. His promise to cut the cost of Novo Nordisk A/S (NYSE:NVO) blockbuster drug Ozempic from around $1,300 to $150 isn't just about affordability—it's about shaking the foundations of the GLP-1 gold rush that's reshaped healthcare valuations from Eli Lilly And Co (NYSE:LLY) to Pfizer Inc (NYSE:PFE).
Read More
Novo Nordisk, Eli Lilly shares drop as Trump promises lower weight loss drug prices
Published: October 17, 2025 by: Proactive Investors
Sentiment: Negative
Shares of Novo Nordisk (NYSE:NVO) and Eli Lilly and Co (NYSE:LLY), two major pharmaceutical companies that produce weight-loss drugs, dropped sharply following comments from US president Donald Trump about reductions in the prices of these medicines. During a White House event focused on fertility treatments and drug pricing, Trump suggested that the cost of drugs like Novo Nordisk's Ozempic (semaglutide), used for diabetes and weight management, would soon be “much lower.
Read More
LLY's Oral GLP-1 Pill Scores Another Pair of Diabetes Wins
Published: October 16, 2025 by: Zacks Investment Research
Sentiment: Positive
Eli Lilly's oral GLP-1 pill orforglipron delivers strong A1C reductions in two late-stage diabetes studies, reinforcing its 2026 filing plans.
Read More
How Will Mounjaro and Zepbound Sales Aid Lilly's Upcoming Q3 Results?
Published: October 16, 2025 by: Zacks Investment Research
Sentiment: Neutral
Strong demand for Mounjaro and Zepbound is expected to power LLY's Q3 growth, as both drugs deepen U.S. and global market reach.
Read More
Eli Lilly: Outstanding Orforglipron Data Reinforces Value Proposition
Published: October 15, 2025 by: Seeking Alpha
Sentiment: Positive
Eli Lilly and Company reported strong Phase 3 results for its oral GLP-1 drug orforglipron in type 2 diabetes, meeting all primary and secondary endpoints. LLY's GLP-1 franchise, including Mounjaro, Zepbound, and orforglipron, underpins its $800bn valuation and continued bullish long-term growth outlook. Despite high valuation and industry headwinds, LLY's management, product pipeline, and market dominance support a 20% upside potential over 18-24 months.
Read More
How LLY Stock Delivered $47 Billion To Shareholders
Published: October 15, 2025 by: Forbes
Sentiment: Positive
In the last decade, Eli Lilly stock (NYSE: LLY) has returned $47 billion to its shareholders via dividends and buybacks. This shareholder-centric approach has delivered solid results in 2025, with the stock posting 9% year-to-date returns, despite experiencing some volatility from its peak of $937 earlier in the year, while demonstrating remarkable resilience in the face of increased competition in the diabetes and obesity treatment markets.
Read More
Eli Lilly: The Rally Has More Room To Run (Rating Upgrade)
Published: October 13, 2025 by: Seeking Alpha
Sentiment: Positive
Eli Lilly stock has recovered resoundingly, outperforming the S&P 500, Novo Nordisk, and healthcare peers after a period of decline. LLY's robust pipeline, expansion into cardiometabolic and oncology adjacencies, and manufacturing readiness support its competitive edge over NVO. Despite near-term gross margin pressures, LLY's valuation is de-risked, and its growth strategy could bolster near-term catalysts from its diversified pipeline.
Read More
Roche, Lilly's blood test for Alzheimer's diagnosis gets US approval
Published: October 13, 2025 by: Reuters
Sentiment: Positive
Roche Diagnostics said on Monday the U.S. Food and Drug Administration cleared its and partner Eli Lilly's blood test as an aid in the initial assessment for Alzheimer's disease.
Read More
AbbVie vs. Eli Lilly: Which Large Drugmaker Has the Edge in 2025?
Published: October 09, 2025 by: Zacks Investment Research
Sentiment: Positive
Lilly's explosive GLP-1 growth and AbbVie's post-Humira rebound set up a fierce 2025 showdown between two pharma powerhouses.
Read More
A Pricing Powerhouse, Now 30% Cheaper: Is Eli Lilly Stock A Buy?
Published: October 09, 2025 by: Forbes
Sentiment: Positive
Eli Lilly (LLY) stock merits your attention. Why? Because it offers monopoly-like high margins at a reduced price.
Read More
Former FDA vaccine chief Peter Marks joins Eli Lilly, STAT reports
Published: October 07, 2025 by: Reuters
Sentiment: Positive
Peter Marks, the former top vaccine regulator at the U.S. Food and Drug Administration, has joined Eli Lilly , STAT News reported on Tuesday.
Read More
Investors Heavily Search Eli Lilly and Company (LLY): Here is What You Need to Know
Published: October 07, 2025 by: Zacks Investment Research
Sentiment: Positive
Zacks.com users have recently been watching Lilly (LLY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Read More
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Published: October 07, 2025 by: Zacks Investment Research
Sentiment: Positive
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Read More
Eli Lilly Stock Rises 16% in a Week: Here's What You Should Know
Published: October 06, 2025 by: Zacks Investment Research
Sentiment: Positive
LLY shares have jumped 16% last week as Pfizer's landmark government deal boosted investor confidence across the pharma sector.
Read More
Trump's Drug Price Cuts: Boom or Bust for These 3 Pharma Giants
Published: October 06, 2025 by: MarketBeat
Sentiment: Neutral
When investors hear that a company will lower prices on its products, their instinctive reaction is to expect a sequential decline in margins and profits, which is not entirely incorrect. However, sometimes these price decreases end up attracting new business, expanding market share, and more than making up for the lost ticket price in the top-line revenue.
Read More
About Eli Lilly and Company (LLY)
- IPO Date 1972-06-01
- Website https://www.lilly.com
- Industry Drug Manufacturers - General
- CEO David A. Ricks
- Employees 47000